XML 53 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)
6 Months Ended
Jun. 30, 2016
May 31, 2016
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2014
Sep. 23, 2014
Jul. 01, 2013
Fair Value of Financial Instruments [Line Items]              
Cash and cash equivalents $ 63,733,000   $ 59,074,000 $ 107,187,000 $ 120,841,000    
Cash equivalents, money market funds 56,800,000   55,800,000        
Fair value of Milestone Rights   $ 44,700,000          
Carrying value 27,623,000   $ 27,613,000        
License and Collaboration Agreement with Sanofi              
Fair Value of Financial Instruments [Line Items]              
Maximum secured loan facility           $ 175,000,000  
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH              
Fair Value of Financial Instruments [Line Items]              
Maximum secured loan facility 175,000,000            
Carrying value 70,300,000            
Estimated fair value 62,000,000            
Milestone Rights Liability | Deerfield | Maximum              
Fair Value of Financial Instruments [Line Items]              
Contingent liability for milestone payments             $ 90,000,000
Milestone Rights Liability | Senior convertible notes due December 31, 2019 | Deerfield              
Fair Value of Financial Instruments [Line Items]              
Long term liability 8,900,000           $ 13,100,000
Fair Value, Inputs, Level 3 | Milestone Rights Liability              
Fair Value of Financial Instruments [Line Items]              
Fair value of Milestone Rights $ 15,600,000            
Fair Value, Inputs, Level 3 | Market Approach Valuation Technique | 5.75% Senior convertible notes due August 15, 2018 | Convertible Debt Securities              
Fair Value of Financial Instruments [Line Items]              
Fair value assumption, risk-free rate 20.00%            
Fair value assumption, stock price volatility 87.50%            
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Sanofi-Aventis Deutschland GmbH              
Fair Value of Financial Instruments [Line Items]              
Market discount rate 11.00%            
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Senior convertible notes due December 31, 2019              
Fair Value of Financial Instruments [Line Items]              
Market discount rate 11.00%            
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Less portion of commitment asset | Senior convertible notes due December 31, 2019              
Fair Value of Financial Instruments [Line Items]              
Market discount rate 11.00%            
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Milestone Rights Liability              
Fair Value of Financial Instruments [Line Items]              
Market discount rate 14.00%